Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1114
Small font sizeDefault font sizeIncrease font size
Navigate here
  Search
 
  
Resource links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (195 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed1819    
    Printed70    
    Emailed1    
    PDF Downloaded254    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 


 
  Table of Contents  
LETTER TO EDITOR
Year : 2011  |  Volume : 48  |  Issue : 4  |  Page : 513-514
 

Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma


Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai, India

Date of Web Publication25-Jan-2012

Correspondence Address:
S Basu
Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-509X.92247

Rights and Permissions



How to cite this article:
Basu S, Tiwari B P. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma. Indian J Cancer 2011;48:513-4

How to cite this URL:
Basu S, Tiwari B P. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma. Indian J Cancer [serial online] 2011 [cited 2019 Aug 24];48:513-4. Available from: http://www.indianjcancer.com/text.asp?2011/48/4/513/92247


Sir,

We appreciate the interest of Dr. James in our research [1] and the concerns he has on this very important subject. We agree with some of the points but want to elaborate related concepts that are evolving at this point, for better understanding.

Very rightly, as the author states, the disease evaluation of prostate carcinoma occurs in three clinical settings and we strongly believe the role of FDG-PET should be assessed in these three settings separately. This has been a persistent flaw in the initial studies published in this domain and requires to be straightened out through systematic examination and debate. On several occasions in clinical practice, we have observed FDG-PET becoming negative much earlier than bone scans, particularly in the context of orchidectomy and hormonal therapy, hence can be considered superior to conventional skeletal scintigraphy in demonstrating therapeutic response early in the course of therapy (at times, in fact, the uptake in the responding bone scan lesions can increase due to sclerosis and 'flare' of osseous lesions). Hence, as stated in our discussion, the history of previous therapy is essential while comparing the two modalities for correct comparison of the two techniques.

Thus, for a head-to-head comparison of the two techniques such understanding becomes pivotal to obviate misinterpretation. Our study demonstrates and emphasizes the need for such patient stratification, whenever one undertakes such endeavor in prostate carcinoma. This is substantiated by the superior performance of FDG-PET in the "untreated" group. While all lesions could not be verified for obvious ethical and practical reasons, the correlative results were taken into account wherever feasible for characterizing a lesion as metastatic. Furthermore, one must recognize the potential of FDG-PET in detecting disease very early during the course of disease when it is confined to the bone marrow, is a major advantage. [2],[3] We must realize that red marrow is the initial sites for development skeletal metastasis and FDG-PET is clearly superior to bone scan in this area. These factors have led to some interesting observations that have been reported in the recent literature [4],[5],[6] with respect to disease detection, prognosis and overall survival.

We agree with the view that the performance of FDG-PET is limited in detecting soft-tissue metastases, particularly in the prostatic bed and in local and regional disease, which is further hampered by the high urinary bladder FDG activity. Hence, newer and novel PET agents have been investigated like 18 F- or 11 C-acetate, and 18 F- or 11C-choline for this purpose; however, more comparative data are needed for definitive conclusion about their precise clinical utility. Also, these agents are not widely available in our country for routine clinical use at this time. About metastases at distant sites, an FDG-PET-CT (which has now almost completely replaced PET-alone modality across the world) would likely to be preferable compared to diagnostic CT alone, because of the advantage of providing whole body status (both skeletal and soft tissue disease) at a significantly lower whole body radiation dose to the patient. Also, baseline scan forms the basis for monitoring therapy once a treatment is instituted. Moreover, the potential of FDG PET-CT for disease prognosis, early treatment monitoring and overall outcome prediction are some of the factors that require to be considered. [4],[5],[6]

Overall, we feel that imaging and the choice of PET tracer (when multiple tracers are available in a center) should be tailored to the specific phases of the disease in a patient-specific manner with the definitive clinical question in mind for a particular indivdual. We strongly believe that better appreciation of the underlying theoretical concepts would further enhance the role and reliability of this powerful imaging modality and would bring about changes in the existing consensus guidelines relating to this important malignancy in the near future.

 
  References Top

1.Tiwari BP, Jangra S, Nair N, Tongaonkar HB, Basu S. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma. Indian J Cancer 2010;47:385-90.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Basu S, Torigian D, Alavi A. Evolving Concept of Imaging Bone Marrow Metastasis in the 21st Century: Critical Role of FDG-PET. Eur J Nucl Med Mol Imaging 2008;35:465-71.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.Basu S, Alavi A. "Bone Marrow" and not "Bone" is the primary site of skeletal metastasis: Critical Role of FDG-PET in this setting. J Clin Oncol 2007;25:1297.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005;11:3210-6.   Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Meirelles GS, Schöder H, Ravizzini GC, Gönen M, Fox JJ, Humm J, et al. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res 2010;16:6093-9.   Back to cited text no. 5
    
6.Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913-8.  Back to cited text no. 6
[PUBMED]  [FULLTEXT]  



This article has been cited by
1 Critical considerations on the combined use of 18F-FDG and 18F-fluoride for PET assessment of metastatic bone disease
Gang Cheng,Thomas C. Kwee,Sandip Basu,Abass Alavi
European Journal of Nuclear Medicine and Molecular Imaging. 2013; 40(8): 1141
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
 

    

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow